Buy Call for Sun Pharma
Market Analysts from HDFC securities had recommended a buy call on Sun Pharma with a target price of Rs 545. The research reports had stated that the Sun Pharma had enhanced its operational performance on all parameters in the US. The Revenue, EBITDA, PAT were growing up by 16%, 14% and 31% YoY respectively in 1QFY20.
Outlook:
In the end, Experts maintain a buy rating on the stock with a target price of Rs 545.
Disclaimer: The perspectives and investment tips are given in this section are the expert’s own and not that of the website or its management. We encourage clients to check with certified experts before taking any position in the stocks/shares mentioned.
